International Myeloma Foundation

MYELOMA MINUTE | Up To The Minute News | 11.16.2023

Prepare for an Intense and Exciting ASH 2023

In this week’s blog, IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie gives an overview of what’s to come during this year’s 65th ASH Annual Meeting and Exposition, which will take place from December 9-12, in San Diego, California and online. With more than 7,000 accepted abstracts “representing the most cutting-edge science in hematology,” myeloma scientific content for this year’s ASH will be jampacked in sessions spanning three days—from Saturday, December 9th to Monday, December 11th. For sessions with overlapping schedules, Dr. Durie advises to use the “teamwork approach” to cover as many abstracts as possible. He makes mention of 2023’s “hot topics”—real-world data, drug access, and racial disparities—and how they will play a major part during this year’s ASH. Dr. Durie recommends enjoying the Thanksgiving break to the fullest to conserve our energies as it will definitely be a bustling few days at ASH 2023 in San Diego.

  

 

Share on Facebook Share on Twitter LinkedIn

Download the New Care Partners Tip Card

Care partners are individuals who provide essential physical, emotional, and practical support to patients with myeloma. Because you walk alongside your loved ones to help them live well with myeloma, the IMF has created this Tip Card specifically for your needs.

  

 

Share on Facebook Share on Twitter LinkedIn

Around the Web: Myeloma News

To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. For this week, we encourage you to explore new data on minimal residual disease (MRD), and how patients who are MRD-negative may be able to stop treatment after two years. In Blood Cancer Journal, this article on how concomitant 1q+ and t(4;14) influences disease, characteristics, immune system, and prognosis in double-hit multiple myeloma was published. JAMA Cardiology released a study showing that patients with multiple myeloma undergoing hematopoietic stem cell transplant (HCT) and clonal hematopoiesis of indeterminate potential (CHIP) had a significantly increased risk of cardiovascular disease post-HCT. This multicenter study reveals how interactions between tumor cells and the immune microenvironment impact treatment responses in newly diagnosed multiple myeloma patients undergoing combination treatments. As always, we invite you to visit the IMF Newsroom for the most recent announcements in myeloma news.

  

 

Share on Facebook Share on Twitter LinkedIn

Did You Know That Medicare May Cover Some Dental Services for Cancer Patients?

For the first time ever, Medicare will cover dental services that are necessary before or during certain cancer treatments. Some examples of these cancer treatments with tandem dental services covered by Medicare include CAR T-cell Therapy and stem cell transplant, among others. The button below provides further details to share with your dental provider.

  

 

Share on Facebook Share on Twitter LinkedIn

Medicare Open Enrollment Period Now Active

Medicare's Open Enrollment Period is October 15 - December 7. This timeframe is your chance to explore Medicare Plans and see what works for you. Plans can change from year to year, and your health needs may change, too. The International Myeloma Foundation and our InfoLine team do not have recommendations about Medicare. We do, however, encourage you to explore Medicare.gov, or contact your local State Health Insurance Assistance Program (SHIP) to get the phone number for Medicare assistance for your state.

  

 

Share on Facebook Share on Twitter LinkedIn

#ASKDRDURIE | Dr. Durie's Weekly Web Video Series

What is high-risk smoldering multiple myeloma?

  

 

Share on Facebook Share on Twitter LinkedIn

Webinar Replays

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Tampa

Watch the Replay
IMF Virtual Regional Community Workshop

See also, all of our events.